How Blood Can Reveal the Future: Predicting Dementia Up to 15 Years in Advance
Recent groundbreaking research opens up the possibility for us to predict dementia not just one or two years in advance—but up to 15 years before clinical symptoms show up. At Velocity Health, we consider these findings to be more than just scientific data. It’s an opportunity for us to put our mission in motion.
A Glimpse of Your Life, Up to 15 Years in the Future
A comprehensive study analyzing over 1,400 blood proteins revealed 11 powerful biomarkers that can forecast dementia with up to 90% accuracy. Leveraging AI to interpret this data, researchers have laid the foundation for predictive screening tools that could soon be as routine as cholesterol tests.
Another study zeroed in on three specific blood markers: pTau217, Neurofilament Light (NfL), and Glial Fibrillary Acidic Protein (GFAP). These biomarkers could detect dementia, including Alzheimer’s, up to a decade in advance, with 83% predictive accuracy—making them strong candidates for wide-scale, community-based screening programs.
How Prediction Can Become Prevention
At Velocity Health, we believe you always have the chance to re-write the end of your life story.
Our precision diagnostics, including DNA analysis, comprehensive blood panels, and advanced neurocognitive profiling, are perfectly designed for scientific advancements in biomarker detection. We catch what others miss—and act before others do.
Based on the implications of this new research, there are several paths that we can help you take if your blood tests reveal that you may be predisposed to dementia:
Early Intervention: Lifestyle changes, neuroprotective therapies, and cognitive resilience strategies, when implemented well before mental decline starts, can diminish dementia’s effects.
Tailored Treatment Plans: Care isn’t guesswork—it’s built around you, your genes, your environment, and your goals.
Smarter Resource Use: For health systems and individuals alike, catching disease early can dramatically reduce cost, stress, and impact. We strive to administer proactive care, rather than trying to mitigate dementia symptoms after memory has already begun to fade.
What’s Next?
We’re thrilled that science is catching up with the future of personalized, proactive healthcare that we envision. But full integration of this dementia detection strategy into everyday care depends on:
Validation across populations to ensure biomarkers work for every background and biology.
Standardized testing to maintain accuracy and trust in results.
Cost-effective rollout into real-world settings—not just labs.
The Velocity Difference
Dementia detection is not meant to fuel any fears you may have of old age. It’s meant to provide you with the freedom to escape the gravity of age-related decline. It’s about making your health story one of power, clarity, and control.
If you’re ready to take ownership of your cognitive longevity, now is the time.
Let us create your precision dementia risk profile and unlock the interventions that work for your unique biology.
This is Velocity Care.
Proactive. Personalized. Powerful.
Key Studies and Sources
1. 15-Year Prediction Horizon Study
Comprehensive research identifying 11 blood biomarkers that predict dementia up to 15 years in advance:
https://www.independent.co.uk/news/science/dementia-research-diagnosis-uk-b2494873.html
2. 10-Year Prediction Horizon Study
Study focusing on tau217, NfL, and GFAP predicting dementia with 83% accuracy:
https://www.scitechdaily.com/blood-test-predicts-dementia-up-to-10-years-in-advance-study-finds
https://medicalxpress.com/news/2025-04-blood-dementia-years-advance.html
3. FDA Clearance of pTau217 Plasma Test
Lumipulse G pTau217/β-Amyloid 1-42 blood test approved for Alzheimer’s: https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease
4. pTau217 Clinical Study (Lancet EBioMedicine)
Lumipulse-G platform’s performance in Alzheimer's detection:
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00441-9/fulltext
5. Biomarker Comparison (Journal of Neurology)
pTau217 vs other biomarkers in a clinical cohort:
https://link.springer.com/article/10.1007/s00415-024-12732-3
6. Neurocode Study on pTau217 Assays
ALZpath vs Fujirebio comparison showing superior pTau217 performance:
https://www.biospace.com/press-releases/neurocode-study-highlights-superior-performance-of-alzpath-ptau217-assay-in-alzheimers-diagnosis
7. Roche’s Elecsys pTau217 Assay FDA Breakthrough Device Designation
https://diagnostics.roche.com/us/en/news-listing/2024/roche-granted-fda-breakthrough-device-designation-ptau217-blood-test-support-earlier-alzheimers-disease-diagnosis.html
